# Pimavanserin for Sleep in Parkinson Disease

> **NCT05796167** · EARLY_PHASE1 · WITHDRAWN · sponsor: **State University of New York - Downstate Medical Center**

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Pimavanserin

## Key facts

- **NCT ID:** NCT05796167
- **Lead sponsor:** State University of New York - Downstate Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01-27
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The PI did not have eligible candidates. Therefore, Acadia Pharmaceuticals (the sponsor) closed the study.
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05796167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05796167, "Pimavanserin for Sleep in Parkinson Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05796167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*